{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:11:01Z","timestamp":1778332261462,"version":"3.51.4"},"reference-count":43,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["17\/34\/01"],"award-info":[{"award-number":["17\/34\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Chronic breathlessness is common and disabling in chronic medical conditions. There is good rationale to use opioids from neuroscience and exercise laboratory studies.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n We assessed the 56-day effectiveness, cost\u2013consequences and safety of long-acting oral morphine for breathlessness in people with cardio-respiratory diseases or cancer.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We conducted a parallel-group, randomised, placebo-controlled trial in 11 UK outpatient services, comparing 10\u201320\u00a0mg daily oral morphine with placebo (and blinded laxative) in people with moderate to severe breathlessness, with embedded health economic evaluation. The primary outcome was\n worst breathlessness<\/jats:italic>\n \/24 hours (0\u201310 numerical rating scale) at day 28. Secondary outcomes included: physical activity levels; worst cough numerical rating scale\/24 hours; Short Form questionnaire-12 items; EuroQol-5 Dimensions, five-level version; morphine-related toxicities; caregiver burden. Analyses were by modified intention-to-treat (modified intention-to-treat; \u2265\u20051 dose of study drug). Primary analysis used repeated measures of covariance adjusted for baseline\n worst breathlessness<\/jats:italic>\n and stratification variables. The planned sample size (90% power, 20% withdrawal) was 158. We undertook two exploratory substudies, a process theory-informed evaluation and an open-label follow-on study.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Between 18 March 2021 and 26 October 2023, 143 were randomised (75 morphine, 68 placebo); 140 formed the modified intention-to-treat population [90% power; males 66%; mean age 70.5 (standard deviation 9.4)]. By day 28, 60\/73 (82%) morphine\n versus<\/jats:italic>\n 56\/67 (84%) placebo participants had \u2265\u200590% adherence.\n <\/jats:p>\n \n At day 28, we found no evidence of a primary outcome difference [adjusted mean difference; 0.09 (95% confidence interval \u22120.57 to 0.75),\n p<\/jats:italic>\n \u2005=\u20050.78], or any secondary measure except improved cough seen at day 56 [adjusted mean difference; \u22121.41 (\u22122.18 to \u22120.64)]. Increased moderate\/vigorous physical activity was seen at day 28 [adjusted mean difference; 9.51 minutes\/day (0.54 to 18.48)], but this was not significant after multiple measures correction. There were 413 adverse events: 251\n versus<\/jats:italic>\n 162 events in 63\/73 (86%) morphine\n versus<\/jats:italic>\n 51\/67 (76%) placebo participants; 18 serious adverse events in 15 participants (morphine, 3\/15 related; placebo, 0\/3 related); no treatment-related deaths. Morphine participants used more inpatient and fewer outpatient services. In the 56-day base-case analysis, morphine was associated with similar mean per-patient costs and quality-adjusted life-years: an increase of \u00a324 (95% confidence interval \u2212\u00a3395 to \u00a3552) and 0.002 (95% confidence interval \u22120.004 to 0.008) quality-adjusted life-years.\n <\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Interpretation is cautious, but findings are plausible and consistent with other evidence. We infer improved exercise endurance. Most participants had chronic lung disease and minoritised ethnic communities are under-represented.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n We found no evidence that morphine improved\n worst breathlessness<\/jats:italic>\n intensity. The pattern of improved physical activity and cough, without increased sleepiness, sedation or cognitive impairment, with good adherence provides rationale for future research. A therapeutic trial of morphine should be evaluated using an exertional task.\n <\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Further research is needed to understand if there is any role of morphine in chronic breathlessness, but our findings do not support its use in this setting. Future studies should consider physical activity levels (actigraphy), exercise endurance (isotime\/isoload breathlessness measures) or cough as the primary outcome. We need better representation from minoritised ethnic communities and people with heart failure.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 17\/34\/01.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/gjmf3819","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T12:25:32Z","timestamp":1755606332000},"page":"1-30","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing the effectiveness, cost-effectiveness and implementation of low-dose oral modified release morphine in people with chronic breathlessness: a synopsis of a RCT and process evaluation"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6204-9158","authenticated-orcid":true,"given":"Miriam J","family":"Johnson","sequence":"first","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-6214","authenticated-orcid":true,"given":"Bronwen","family":"Williams","sequence":"additional","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5459-6178","authenticated-orcid":true,"given":"Catriona","family":"Keerie","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, University of Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6186-6794","authenticated-orcid":true,"given":"Sharon","family":"Tuck","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, University of Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-9559","authenticated-orcid":true,"given":"Simon P","family":"Hart","sequence":"additional","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5338-8107","authenticated-orcid":true,"given":"Sabrina","family":"Bajwah","sequence":"additional","affiliation":[{"name":"Cicely Saunders Institute of Palliative Care Policy and Rehabilitation, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-6996","authenticated-orcid":true,"given":"Nazia","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"Department of Life and Health Sciences, School of Medicine, Ulster University, Coleraine, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-7421","authenticated-orcid":true,"given":"Mark","family":"Pearson","sequence":"additional","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-3521","authenticated-orcid":true,"given":"Judith","family":"Cohen","sequence":"additional","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-868X","authenticated-orcid":true,"given":"Rachael A","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Respiratory Sciences, NIHR Leicester Biomedical Research Centre \u2013 Respiratory, University of Leicester, Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1988-1250","authenticated-orcid":true,"given":"David C","family":"Currow","sequence":"additional","affiliation":[{"name":"Flinders Ageing Alliance, Flinders University, Adelaide, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3687-1313","authenticated-orcid":true,"given":"Irene J","family":"Higginson","sequence":"additional","affiliation":[{"name":"Cicely Saunders Institute of Palliative Care Policy and Rehabilitation, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6015-7841","authenticated-orcid":true,"given":"Peter S","family":"Hall","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Centre, The University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1628-7427","authenticated-orcid":true,"given":"Marek","family":"Atter","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Centre, The University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9823-9252","authenticated-orcid":true,"given":"John","family":"Norrie","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0034-5814","authenticated-orcid":true,"given":"Charlotte","family":"Thompson","sequence":"additional","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3627-7218","authenticated-orcid":true,"given":"Chao","family":"Huang","sequence":"additional","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5566-8740","authenticated-orcid":true,"given":"Lukas","family":"Pitel","sequence":"additional","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Jones","sequence":"additional","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8193-7050","authenticated-orcid":true,"given":"Gareth","family":"Stewart","sequence":"additional","affiliation":[{"name":"NHS Lothian, Western General Hospital, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9214-0091","authenticated-orcid":true,"given":"Marie T","family":"Fallon","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Centre, The University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"key2026050918094400_ref1-bib1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S2213-2600(25)00205-X","article-title":"Morphine for chronic breathlessness (MABEL): in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial","volume":"13","author":"Johnson","year":"2025","journal-title":"Lancet Respir Med"},{"key":"key2026050918094400_ref2-bib2","doi-asserted-by":"crossref","first-page":"00167","DOI":"10.1183\/23120541.00167-2023","article-title":"Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol","volume":"9","author":"Date","year":"2023","journal-title":"ERJ Open Res"},{"key":"key2026050918094400_ref3-bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-102124","article-title":"Morphine for chronic breathlessness (MABEL) in the UK: a health economic evaluation of a multisite, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial","volume":"15","author":"Atter","year":"2025","journal-title":"BMJ Open"},{"key":"key2026050918094400_ref4-bib4","article-title":"What enables the safe prescription and monitoring of morphine for chronic breathlessness? Insights from a Normalisation Process Theory-informed implementation survey and interviews with clinicians","author":"Pearson","year":"2025","journal-title":"medRxiv"},{"key":"key2026050918094400_ref5-bib5","doi-asserted-by":"crossref","first-page":"1902202","DOI":"10.1183\/13993003.02202-2019","article-title":"Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness","volume":"56","author":"Ekstrom","year":"2020","journal-title":"Eur Respir J"},{"key":"key2026050918094400_ref6-bib6","doi-asserted-by":"crossref","first-page":"00823","DOI":"10.1183\/23120541.00823-2020","article-title":"Minimal clinically important difference for daily pedometer step count in COPD","volume":"7","author":"Polgar","year":"2021","journal-title":"ERJ Open Res"},{"key":"key2026050918094400_ref7-bib7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1183\/09031936.00139812","article-title":"Opioids for chronic refractory breathlessness: patient predictors of beneficial response","volume":"42","author":"Johnson","year":"2013","journal-title":"Eur Respir J"},{"key":"key2026050918094400_ref8-bib8","doi-asserted-by":"crossref","first-page":"e829","DOI":"10.1136\/spcare-2022-003693","article-title":"Morphine for chronic breathlessness in COPD: improvement predictors-cross-sectional study","volume":"13","author":"Verberkt","year":"2023","journal-title":"BMJ Support Palliat Care"},{"key":"key2026050918094400_ref9-bib9","doi-asserted-by":"crossref","first-page":"2400335","DOI":"10.1183\/13993003.00335-2024","article-title":"European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness","volume":"63","author":"Holland","year":"2024","journal-title":"Eur Respir J"},{"key":"key2026050918094400_ref10-bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/SPC.0000000000000444","article-title":"Why treatment efficacy on breathlessness in laboratory but not daily life trials? The importance of standardized exertion","volume":"13","author":"Ekstr\u00f6m","year":"2019","journal-title":"Curr Opin Support Palliat Care"},{"key":"key2026050918094400_ref11-bib11","doi-asserted-by":"crossref","first-page":"2201484","DOI":"10.1183\/13993003.01484-2022","article-title":"The effect of regular, low-dose, sustained-release morphine on routine physical activity in people with persistent breathlessness \u2013 a hypothesis-generating study","volume":"60","author":"Ferreira","year":"2022","journal-title":"Eur Respir J"},{"key":"key2026050918094400_ref12-bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12931-023-02384-8","article-title":"The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial","volume":"24","author":"Friedrich","year":"2023","journal-title":"Respir Res"},{"key":"key2026050918094400_ref13-bib13","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jpainsymman.2019.07.026","article-title":"A randomized, double-blind, multisite, pilot, placebo-controlled trial of regular, low-dose morphine on outcomes of pulmonary rehabilitation in COPD","volume":"58","author":"Kochovska","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"key2026050918094400_ref14-bib14","doi-asserted-by":"crossref","first-page":"e110835","DOI":"10.1371\/journal.pone.0110835","article-title":"Improving understanding of and adherence to pulmonary rehabilitation in patients with COPD: a qualitative inquiry of patient and health professional perspectives","volume":"9","author":"Guo","year":"2014","journal-title":"PLOS ONE"},{"key":"key2026050918094400_ref15-bib15","doi-asserted-by":"crossref","first-page":"12619","DOI":"10.1038\/s41598-024-62896-1","article-title":"Interaction analysis of subgroup effects in randomized trials: the essential methodological points","volume":"14","author":"Fingerhut","year":"2024","journal-title":"Sci Rep"},{"key":"key2026050918094400_ref16-bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12904-025-01670-0","article-title":"BreathCarer: informal carers of patients with chronic breathlessness: a mixed-methods systematic review of burden, needs, coping, and support interventions","volume":"24","author":"Bl\u00fctgen","year":"2025","journal-title":"BMC Palliat Care"},{"key":"key2026050918094400_ref17-bib17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/geront\/41.5.652","article-title":"The Zarit Burden Interview: a new short version and screening version","volume":"41","author":"B\u00e9dard","year":"2001","journal-title":"Gerontologist"},{"key":"key2026050918094400_ref18-bib18","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1136\/bmjspcare-2016-001288","article-title":"Developing the methods and questionnaire (VOICES-SF) for a national retrospective mortality follow-back survey of palliative and end-of-life care in England","volume":"9","author":"Hunt","year":"2019","journal-title":"BMJ Support Palliat Care"},{"key":"key2026050918094400_ref19-bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/02692163231211227","article-title":"The impact of regular, low-dose, sustained-release morphine for chronic breathlessness on caregiver burden: an exploratory analysis of the BEAMS trial","volume":"38","author":"Kochovska","year":"2024","journal-title":"Palliat Med"},{"key":"key2026050918094400_ref20-bib20","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1001\/jama.2022.20206","article-title":"Effect of regular low-dose extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease: the BEAMS randomized clinical trial","volume":"328","author":"Ekstr\u00f6m","year":"2022","journal-title":"JAMA"},{"key":"key2026050918094400_ref21-bib21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.amjmed.2014.07.015","article-title":"Elucidating risk factors for androgen deficiency associated with daily opioid use","volume":"127","author":"Rubinstein","year":"2014","journal-title":"Am J Med"},{"key":"key2026050918094400_ref22-bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/2049463712438299","article-title":"Opioids and the immune system","volume":"6","author":"Seyfried","year":"2012","journal-title":"Br J Pain"},{"key":"key2026050918094400_ref23-bib23","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamainternmed.2020.3134","article-title":"Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial","volume":"180","author":"Verberkt","year":"2020","journal-title":"JAMA Intern Med"},{"key":"key2026050918094400_ref24-bib24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ehf2.12498","article-title":"Oral modified release morphine for breathlessness in chronic heart failure: a randomised placebo-controlled trial","volume":"6","author":"Johnson","year":"2019","journal-title":"ESC Heart Fail"},{"key":"key2026050918094400_ref25-bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1089\/jpm.2022.0381","article-title":"Testosterone levels in people taking regular, low-dose, sustained-release morphine for persisting breathlessness \u2013 an exploratory study","volume":"26","author":"Ferreira","year":"2023","journal-title":"J Palliat Med"},{"key":"key2026050918094400_ref26-bib26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jpainsymman.2010.11.021","article-title":"Once daily opioids for chronic dyspnoea: a dose increment and pharmacovigilance study","volume":"42","author":"Currow","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"key2026050918094400_ref27-bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1089\/jpm.2012.0270","article-title":"Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough","volume":"16","author":"Oxberry","year":"2013","journal-title":"J Palliat Med"},{"key":"key2026050918094400_ref28-bib28","volume-title":"Nomad: Implementation Measure Based on Normalization Process Theory [Measurement instrument]","author":"Finch","year":"2015"},{"key":"key2026050918094400_ref29-bib29","doi-asserted-by":"crossref","first-page":"210105","DOI":"10.1183\/16000617.0105-2021","article-title":"Sex and gender in interstitial lung diseases","volume":"30","author":"Kawana-Daurado","year":"2021","journal-title":"Eur Respir Rev"},{"key":"key2026050918094400_ref30-bib30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2023","journal-title":"Lancet Respir Med"},{"key":"key2026050918094400_ref31-bib31","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.3399\/bjgp12X625120","article-title":"Effect of ethnicity on the prevalence, severity, and management of COPD in general practice","volume":"62","author":"Martin","year":"2012","journal-title":"Br J Gen Pract"},{"key":"key2026050918094400_ref32-bib32","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S2213-2600(23)00125-X","article-title":"Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?","volume":"11","author":"Chua","year":"2023","journal-title":"Lancet Respir Med"},{"key":"key2026050918094400_ref33-bib33","volume-title":"Ethnic Group by Age and Sex, England and Wales: Census","author":"Office of National Statistics","year":"2021"},{"key":"key2026050918094400_ref34-bib34","doi-asserted-by":"crossref","first-page":"e087627","DOI":"10.1136\/bmjopen-2024-087627","article-title":"All the voices we cannot hear: a taxonomy of why some populations\u2019 experiences are missing from health and care quality evidence and the Toolkit for Assessing Under Representation in User Surveys (TAURUS)","volume":"15","author":"Graham","year":"2025","journal-title":"BMJ Open"},{"key":"key2026050918094400_ref35-bib35","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/ehf2.12556","article-title":"Targeting breathlessness in heart failure","volume":"6","author":"Coats","year":"2020","journal-title":"ESC Heart Fail"},{"key":"key2026050918094400_ref36-bib36","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1177\/02692163211032114","article-title":"Professionals\u2019, patients\u2019, and families\u2019 views on the use of opioids for chronic breathlessness: a systematic review using the framework method and pillar process","volume":"35","author":"Reedy","year":"2021","journal-title":"Palliat Med"},{"key":"key2026050918094400_ref37-bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12931-024-02897-w","article-title":"The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis","volume":"25","author":"Green","year":"2024","journal-title":"Respir Res"},{"key":"key2026050918094400_ref38-bib38","volume-title":"P-279 Impact on Participant Recruitment of Adding an Infographic to a Patient Information Leaflet in the MABEL trial, a Study Within a Trial (SWAT116). OSF Meetings\/International Clinical Trials, Methodology Conference (ICTMC)","author":"Northgraves","year":"2024"},{"key":"key2026050918094400_ref39-bib39","volume-title":"P-334 The Advantages and Disadvantages of Using a Centrally Managed ActiGraph Distribution System for Collecting Physical Activity Data in a Multicentre Randomised Controlled Trial. OSF Meetings\/International Clinical Trials, Methodology Conference (ICTMC)","author":"Williams","year":"2024"},{"key":"key2026050918094400_ref40-bib40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/thoraxjnl-2016-209868","article-title":"One evidence base; three stories: do opioids relieve chronic breathlessness?","volume":"73","author":"Ekstr\u00f6m","year":"2018","journal-title":"Thorax"},{"key":"key2026050918094400_ref41-bib41","doi-asserted-by":"crossref","first-page":"e001038","DOI":"10.1136\/esmoopen-2020-001038","article-title":"Management of breathlessness in patients with cancer: ESMO Clinical Practice Guidelines","volume":"5","author":"Hui","year":"2020","journal-title":"ESMO Open"},{"key":"key2026050918094400_ref42-bib42","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S2213-2600(24)00376-X","article-title":"James Lind Alliance Breathlessness PSP steering group. Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership","volume":"13","author":"Evans","year":"2025","journal-title":"Lancet Respir Med"},{"key":"key2026050918094400_ref43-bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12966-021-01157-0","article-title":"Association of daily composition of physical activity and sedentary behaviour with incidence of cardiovascular disease in older adults","volume":"18","author":"Yerramalla","year":"2021","journal-title":"Int J Behav Nutr Phys Act"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2051033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GJMF3819\/GJMF3819.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2051033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T12:43:35Z","timestamp":1778330615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/GJMF3819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"alternative-id":["10.3310\/GJMF3819"],"URL":"https:\/\/doi.org\/10.3310\/gjmf3819","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"03-2019","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"04-2025","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"10-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}